Press Releases

Media Inquiries - media@caredxinc.com

 
Press Releases
Date Title and Summary View
Aug 15, 2017 BRISBANE, Calif., Aug. 15, 2017 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announced that Peter Maag, PhD., Chief Executive Officer, and Michael Bell, Chief F...
Aug 10, 2017 BRISBANE, Calif., Aug. 10, 2017 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today reported financial results for the second quarter ended June 30, 2017. Recent ...
Aug 4, 2017 BRISBANE, Calif., Aug. 04, 2017 (GLOBE NEWSWIRE) -- CareDx, Inc. (NASDAQ:CDNA), a molecular diagnostics company focusing on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, described rigorous evidence of the analytical robustness of AlloSure testing at the annu...
Jul 27, 2017 BRISBANE, Calif., July 27, 2017 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announced that it will release financial results for the second quarter 2017 after ...
Jul 13, 2017 BRISBANE, Calif., July 13, 2017 (GLOBE NEWSWIRE) -- CareDx, Inc. (NASDAQ:CDNA), a molecular diagnostics company focusing on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, announced today that the landmark 100,000th AlloMap result has been provided. The i...
Jul 3, 2017 BRISBANE, Calif., July 03, 2017 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today reported that it has signed agreements that restructure and extend the maturity of ...
Jun 9, 2017 BRISBANE, Calif., June 09, 2017 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today reported financial results for the first quarter ended March 31, 2017. "We are...
May 30, 2017 BRISBANE, Calif., May 30, 2017 (GLOBE NEWSWIRE) -- CareDx, Inc. (NASDAQ:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, will highlight CareDx's Olerup pre-transplant diagnostics at the 31st European Immunogenet...
May 22, 2017 BRISBANE, Calif., May 22, 2017 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announced that, as expected, on May 22, 2017 it received a standard notification let...
May 22, 2017 BRISBANE, Calif., May 22, 2017 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today reported preliminary financial results for the first quarter ended March 31, 2017. ...
Page:
1
... NextLast
= add release to Briefcase